ARTICLE SUMMARY:
In October, Fractyl Health reported positive six-month top-line results from the pivotal trial of Revita, a novel device-based therapy designed to help patients maintain weight loss after discontinuing GLP-1 drugs.
When Fractyl Health was founded in 2010, it was the first company to target the duodenal mucosa with an energy-based therapy. Its Revita Duodenal Mucosal Resurfacing (Revita-DMR) procedure is designed to reverse metabolic dysfunction associated with unhealthy diets. The premise is that diets high in ultra-processed foods can alter the duodenal mucosa, disrupting gut-to-brain signaling involved in hunger and satiety. By ablating portions of the mucosa, Fractyl aims to stimulate regeneration and restore healthier metabolic signaling.
The hydrothermal ablation procedure is performed endoscopically in a single outpatient session, using techniques familiar to gastroenterologists and bariatric surgeons. It does not alter gastrointestinal anatomy or preclude other metabolic treatments.
Fractyl initially set out to develop a non-pharmacological treatment for type 2 diabetes, a substantial market opportunity. More recently, however, the company has turned its attention to what may be an even more immediate unmet need: helping patients sustain weight loss after stopping GLP-1 receptor agonists, the highly successful class of obesity drugs.